Special Issue "Bioengineering Techniques and Applications Against COVID-19"

A special issue of Bioengineering (ISSN 2306-5354).

Deadline for manuscript submissions: closed (30 April 2021).

Special Issue Editors

Dr. Dimitrios Glotsos
Guest Editor
Biomedical Engineering Department, University of West Attica, Athens, Greece
Interests: image processing; machine learning
Dr. Luis Coelho
E-Mail Website
Guest Editor
CIETI, Polytechnic Institute of Porto, Porto, Portugal
Interests: physiological signal processing; image processing; machine learning; neurodegenerative diseases; virtual reality
Special Issues, Collections and Topics in MDPI journals
Dr. Sara Reis
Guest Editor
CIETI, Polytechnic Institute of Porto, Portugal
Interests: health innovation; bioethics

Special Issue Information

Dear Colleagues,

Coronavirus disease (COVID-19) is a disease caused by a newly discovered coronavirus. Most people infected with the virus will experience no symptoms or mild to moderate respiratory illness and recover without special treatment. However, the disease can be severe, especially on older persons and those with pre-existing medical conditions (such as high blood pressure, heart problems or diabetes). The disease is highly contagious and has evolved into a pandemic, bringing several social, economic, and health challenges.

Considering the current context and the situation of uncertainty regarding the future, the scientific community has contributed with technological advances in several areas in order to combat the evolution of the disease and its consequences.

In this Special Edition, we would like to receive innovative contributions on bioengineering techniques and applications against COVID-19. Authors are invited to submit original, unpublished papers on topics including but not limited to:

  • Disease prevention techniques;
  • Simulations that make it possible to predict the behavior of the virus;
  • Development, optimization, and validation of early diagnosis methods, within a framework of training and national autonomy for the COVID diagnosis;
  • Methods for early detection of the infection and for disease prognosis;
  • Characterization of the immune response, immunopathology, and immunogenetic factors;
  • Development of new therapies or new therapeutic approaches or protocols;
  • Clinical studies for management and monitoring of infected individuals and risk groups using computational approaches;
  • Equipment or devices to improve the response of health systems;
  • Support tools to help clinic decision making processes in scarce resource environments.

Prof. Dr. Dimitrios Glotsos
Dr. Luis Coelho
Dr. Sara Reis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • COVID-19 
  • Simulation models 
  • Computational approaches 
  • Support Tools

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Analysis and Forecasting Incidence, Intensive Care Unit Admissions, and Projected Mortality Attributable to COVID-19 in Portugal, the UK, Germany, Italy, and France: Predictions for 4 Weeks Ahead
Bioengineering 2021, 8(6), 84; https://doi.org/10.3390/bioengineering8060084 - 11 Jun 2021
Viewed by 1327
The use of artificial neural networks (ANNs) is a great contribution to medical studies since the application of forecasting concepts allows for the analysis of future diseases propagation. In this context, this paper presents a study of the new coronavirus SARS-COV-2 with a [...] Read more.
The use of artificial neural networks (ANNs) is a great contribution to medical studies since the application of forecasting concepts allows for the analysis of future diseases propagation. In this context, this paper presents a study of the new coronavirus SARS-COV-2 with a focus on verifying the virus propagation associated with mitigation procedures and massive vaccination campaigns. There were two proposed methodologies in making predictions 28 days ahead for the number of new cases, deaths, and ICU patients of five European countries: Portugal, France, Italy, the United Kingdom, and Germany. A case study of the results of massive immunization in Israel was also considered. The data input of cases, deaths, and daily ICU patients was normalized to reduce discrepant numbers due to the countries’ size and the cumulative vaccination values by the percentage of population immunized (with at least one dose of the vaccine). As a comparative criterion, the calculation of the mean absolute error (MAE) of all predictions presents the best methodology, targeting other possibilities of use for the method proposed. The best architecture achieved a general MAE for the 1-to-28-day ahead forecast, which is lower than 30 cases, 0.6 deaths, and 2.5 ICU patients per million people. Full article
(This article belongs to the Special Issue Bioengineering Techniques and Applications Against COVID-19)
Show Figures

Figure 1

Back to TopTop